Sung-bae B. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: December 10, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer.

A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer.

Journal: Journal of breast cancer

Published: October 13, 2025

Serial analysis of ESR1 mutations in cell-free DNA from hormone receptor-positive, HER2-negative metastatic breast cancer during palliative endocrine therapy.

Serial analysis of ESR1 mutations in cell-free DNA from hormone receptor-positive, HER2-negative metastatic breast cancer during palliative endocrine therapy.

Journal: Frontiers in oncology

Published: September 20, 2025

Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7).

Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7).

Journal: Breast (Edinburgh, Scotland)

Published: September 09, 2025

Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4).

Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4).

Journal: Breast (Edinburgh, Scotland)

Published: September 09, 2025

OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.

OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 26, 2025

Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy.

Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy.

Journal: Clinical breast cancer

Published: May 22, 2025

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: December 11, 2024

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2024

Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in De Novo Stage IV Breast Cancer Patients.

Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in De Novo Stage IV Breast Cancer Patients.

Journal: Journal of breast cancer

Published: November 04, 2024

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors.

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 28, 2024

Showing 1-12 of 140

Last Updated: 09/26/2026